EWTX · Edgewise Therapeutics, Inc.
$43.29
-3.15 (-6.78%)
At close · Aug 20
Market Cap
$5.02B
Shares
108.60M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher Martin | Class I director | Appointed | 2025-11-20 |
| Michael Carruthers | Chief Financial Officer | Retired | 2025-11-10 |
| Michael Nofi | Chief Financial Officer | Appointed | 2025-11-10 |
| Behrad Derakhshan | Chief Operating Officer | Appointed | 2025-01-22 |
| Arlene Morris | Class I director | Appointed | 2024-05-07 |
| Kenneth Harrison | Board | Resigned | 2023-06-22 |
| Dr. Jonathan Fox | Class III director | Appointed | 2023-03-06 |
Key facts
CIK
1710072
CUSIP
28036F105
13F (30d)
212 filings
208 filers
Visit website
Investor relations